å»è¬åå ¬è¡šãããæŽå¯
ã¢ã³ãã»ã³ã¹ãªãªãŽãã¯ã¬ãªãã åžå ŽèŠæš¡ãšäºæž¬ â 2025 â 2032äžçã®ã¢ã³ãã»ã³ã¹ãªãªãŽãã¯ã¬ãªãã åžå ŽèŠæš¡ã¯ã2025幎ã®USD 2.18åã§è©äŸ¡ããããšæšå®ããã2032幎ãŸã§ã«USD 5.35åãã«ã«éãããšäºæ³ããã2025幎ãã2032幎ãŸã§ã®13.4%ã®ååç©å¹Žéæé·ç(CAGR)ãå±ç€ºããŠããŸãããããã£ãŒã«åºåœ¢ãªãªãŽãã¯ã¬ãªãã(ASO)ã¯ãç¹å®ã®ã¡ãã»ã³ãžã£ãŒRNA(mRNA)ã®ã·ãŒã±ã³ã¹ã«çµåããããã«èšèšãããæ žé žã®çãåæéã§ãããã«ãã£ãŠéºäŒåçºçŸã調ç¯ããã ãã®åžå Žã§ã®è£œåã¯ãäž»ã«Duchenneçãžã¹ãããã£ãŒãèé«çèçž®ãç¹å®ã®çãªã©ã®éºäŒçããã³... ãã£ãšèŠã
ç¥çµå€æ§çŸæ£æ²»çåžå Žã¯ç±³ãã«45,127.8ã§è©äŸ¡ããããšæšå®ããã 2025幎ã®Mnã¯USD 56,184.0ã«éãããšäºæ³ãããŸã 2032幎ã®Mnã¯2025幎ãã2032幎ã«ãããŠ3.18%ã®æ··åç©ã®å¹Žéæé·ç(CAGR)ãå±ç€ºããŸãã ç¥çµå€æ§çŸæ£ åžå Žã¯ãç¥çµå€æ§çŸæ£ã®èå»¶ã«äžæããäžçäžã®è(èå)ã®äººå£ã«äžæãã匷ãæé·ãçµéšããŠããŸãã ãŸããå®å šã§å¹æçãªæ²»çè¬ã®éèŠã®å¢å ãšãç¥çµå€æ§çŸæ£ããã³å©çšå¯èœãªæ²»çè¬ã«é¢ãã人ã ã®éã§æèã®å¢å ãåžå Žã®æé·ãé«ããããšãæåŸ ãããŸãã ããããç¥çµå€æ§çŸæ£æ²»ç補åã®å³ããèŠå¶ã¬ã€ãã©ã€ã³ãç¹èš±è©Šéšã¯ãåžå Žã®æé·ã劚ããããšãæåŸ ãã... ãã£ãšèŠã
ãã§ãã«ã¢ã©ãã³ åžå ŽèŠæš¡ãšäºæž¬ â 2025 â 2032ã°ããŒãã«ãã§ãã«ã¢ã©ãã³ åžå ŽèŠæš¡ã¯ã2025幎ã®USD 1.72åã§è©äŸ¡ããããšæšå®ããã2032幎ãŸã§ã®USD 2.85åã«éãããšäºæ³ããã2025幎ãã2032幎ãŸã§ã®7.4%ã®ååç©å¹Žéæé·ç(CAGR)ãå±ç€ºããŠããŸãããããã£ãŒã«Phenylalanineãããã¯ãã¯é£ç³§ãè¬å€ããã³äŸçµŠã®äŒæ¥ã®äž»äžéç©ãšããŠäœ¿çšãããèªç¶ãª(L-ãã§ãã«ã¢ã©ãã³)ããã³åæã®åœ¢æ ã§ã¢ããé žãå«ãã§ããŸãã L-ãã§ãã«ã¢ã©ãã³ã¯ãã¿ã³ãã¯è³ªã®ãã«ãã£ã³ã°ãããã¯ãšããŠæ©èœããã¢ã¹ãã«ããŒã ãªã©ã®äººå·¥ç峿ã®ãã¬ã«ã¹ã¿ãŒãšããŠæ©èœããŸã... ãã£ãšèŠã
Nerveä¿®çããã³åçåžå ŽèŠæš¡ãšäºæž¬ - 2025 - 20322025幎ãã2032幎ãŸã§ã®USD 8.4åç±³ãã«ã«çžåœããäžççãªNerveã®ä¿®çããã³åçã®åžå ŽèŠæš¡ãæšå®ããã2032幎ãŸã§ã«USD 14.6åç±³ãã«ã«éãããšäºæ³ãããããããã£ãŒã«ç¥çµä¿®åŸ©ããã³åç補åã¯ãçäœææãç¥çµåºæ¿è£ 眮ãç¥çµæ°Žè·¯ãããã³æå·ããç¥çµéã®å埩ã«åœ¹ç«ã€æé·å åããŒã¹ã®æ²»çæ³ã§æ§æãããŠããŸãã äž»èŠãªè£œåã«ããŽãªã«ã¯ããã€ãªãšã³ãžãã¢ãªã³ã°ç¥çµã¬ã€ãã³ã¹ã³ã³ãžãã(NGC)ãå å·¥ã¢ãœã°ã©ãããããã³è»žåæé·ããµããŒãããåæããªããŒããŒã¹ã®è¶³å Žãå«ãŸããŸãã 黿°åºæ¿è£ 眮ããã³ç¥çµèª¿ç¯ã®æ³šå ¥ã¯ãŸ... ãã£ãšèŠã
ãã³ã¿ãŒçå矀治çåžå ŽèŠæš¡ãšäºæž¬ - 2025 - 2032äžççãªãã³ã¿ãŒã·ã³ãããŒã æ²»çåžå ŽèŠæš¡ã¯ã2025幎ãã2032幎ãŸã§ã®USD 1.27åã§è©äŸ¡ããããšæšå®ãããUSD 2.14åç±³ãã«ã«éãããšäºæ³ãããããããã£ãŒã«ãã³ã¿ãŒçåçŸ€ã®æ²»çã«ã¯ãé µçŽ ä»£æ¿çæ³(ERT)ãéºäŒåæ²»çè¬ãåºè³ªæžå°å€ãç²èå€ç³çII(MPS II)ã®çç¶ã管çããããã«èšèšãããæ¯æçæ³è¬ãå«ãŸããŸãã mainstay 補å㯠iduronate-2-sulfatase é µçŽ ã§ãã idursulfase ããã³ãã®å€ç°äœãªã©ãéæŽ»æ§ãªé µçŽ æŽ»æ§ãå埩ããããã«éèçã«æäžãããŸãã æè¿ã®è£œå驿°ã¯ã... ãã£ãšèŠã
åå®®çã¯åžå ŽèŠæš¡ãšäºæž¬ããã©ãã° - 2025 - 2032ã°ããŒãã«ãŠãã«ãªã³ããè¬åžå ŽèŠæš¡ã¯ã2025幎ãã2032幎ãŸã§ã®USD 1.75åç±³ãã«ã§è©äŸ¡ãããUSD 3.15åç±³ãã«ã«éãããšäºæ³ãããããããã£ãŒã«åå®®çè¬ã«ã¯ãååŠçæ³å€(ã«ã«ããã©ãã³ããã¯ãªã¿ãã»ã«)ããã«ã¢ã³çæ³(ããã²ã¹ãã³ãã¢ããã¿ãŒãŒé»å®³å€)ãæšçå€(ã¬ããããããšãããªã )ãããã³å ç«çæ³(ããããªãºããããã¹ã¿ãªãã)ãå«ãŸããŸãã ãããã®è£œåã¯ãåç¬ãŸãã¯çµã¿åãããŠæ²»çãã ã€ã³ããã¯ã¹ ãããŠä»ã®åå®®çã çµå£ãéèå ããã³æ³šå°å¯èœãªåŠæ¹ã¯ãè¬ã®çš®é¡ããã³æ²»ç段éã«å¿ããŠå©çšã§ããŸãã å€ãã®æ°... ãã£ãšèŠã
é²è å€ å»è¬ååžå Žã¯ã2025幎ã«USD 7.48 Bnã§è©äŸ¡ããã2032幎ã«USD 9.39 Bnã«éãããšäºæ³ããã2025幎ãã2032幎ãŸã§ã®3.3%ã®ååç©ã®å¹Žéæé·ç(CAGR)ãå±ç€ºããŠããŸãã ã°ããŒãã«é²è è¬åžå Žã«é¢ããã¢ããªã¹ãã®æèŠ: é²é£è¬ã¯ãè±æ°Žå€ã®æ²»çãšäºé²ã«åœ¹ç«ã¡ãŸãã®ã§ãææ±è¬ãšããŠãç¥ãããŠããŸãã é²é£è¬ã¯ãäžè¬ã«2ã€ã®ã¿ã€ãã«åé¡ãããŸã:åºã¹ãã¯ãã«ã®æã»ãã·ã§ã³è¬ããã³çã¹ãã¯ãã«ã®æã»ãã·ã§ã³è¬ã ãããŒããŠã§ã€ ã¹ãã¯ãã« antiseizureã®è¬ã¯sizureã®ã¿ã€ãã®åºãç¯å²ããçãã¹ãã¯ãã«ã®antiseizureã®è¬ç©ãäž»ã«çŠç¹ãæ±ããŸ... ãã£ãšèŠã
çåè§£æ§ããªããŒåžå ŽèŠæš¡ãšäºæž¬ - 2025 - 20322025幎ã®USD 1.1åã§ãã°ããŒãã«ãã€ãªã¬ãŸã©ãã«ããªããŒåžå ŽèŠæš¡ãè©äŸ¡ããããšæšå®ããã2032幎ãŸã§ã«2.2åç±³ãã«ã«éãããšäºæ³ããã2025幎ãã2032幎ãŸã§ã®10.4%ã®ååç©å¹Žéæé·ç(CAGR)ãå±ç€ºããŠããŸãããããã£ãŒã«çåè§£æ§ããªããŒã¯ãäœå ã§å®å šã«å£åãããããã«èšèšãããå»çã°ã¬ãŒãã®ææã§ãã 補åã«ã¯ãåžåãããåã«äžæçãªæ§é ãµããŒããæäŸããçž«åãã€ã³ãã©ã³ããã¹ãã³ããããã³è¶³å Žãå«ãŸããŸããé€å»æé ã®å¿ èŠæ§ãæé€ããŸãã ãããã®ããªããŒã¯ãå¶åŸ¡ãããå£åçãçäœé©åæ§ãããã³æŽåœ¢å€ç§ãå¿è¡... ãã£ãšèŠã
ã«ããžãµã«ã³ã æ²»çåžå ŽèŠæš¡ãšäºæž¬ - 2025 - 2032äžçã®ã«ããžãµã«ã³ã æ²»çåžå ŽèŠæš¡ã¯ã2025幎ã®USD 580.4çŸäžã§è©äŸ¡ããã2032幎ãŸã§ã®7.8%ã®æ··åç©ã®å¹Žéæé·ç(CAGR)ã2025ãã2032幎ãŸã§æºãããšäºæ³ãããŸãããããã£ãŒã«ã«ããžãµã«ãã®æ²»ç補åã¯ãååŠçæ³å€ãå ç«èª¿ç¯å€ãããã³è «ç墿®ããã³è¡ç®¡åœ¢æãé»å®³ããæšççæ³ãå«ã¿ãŸãã 補åã¯ã泚å°å¯èœãªååŠçæ³ããçµå£å°ååè¬ããã³ã¢ãã¯ããŒãã«æäœãžã®ç¯å²ã¯ãç¹ã«ç å€ã®å¢æ®ãæžããããã«èšèšãããŠããŸãã ãããã®çæ³ã¯ãæ£ç¢ºãªæè¬ãæå°éã®æ¯æ§ãããã³æã¬ãããŠã€ã«ã¹æ²»çãšã®äºææ§ã®ããã«åŠæ¹ãããå šèº«... ãã£ãšèŠã
ææçæ²»çè¬åžå ŽèŠæš¡ãšäºæž¬ - 2025 - 2032ã°ããŒãã«ææçã®æ²»ç åžå ŽèŠæš¡ã¯ã2025幎ã«74.8åç±³ãã«ã§è©äŸ¡ããã2032幎ãŸã§ã«116.5åç±³ãã«ã«éããèŠèŸŒã¿ã§ã2025幎ãã2032幎ãŸã§ã®6.8%ã®ååç©å¹Žéæé·ç(CAGR)ãå±ç€ºããŠããŸãããããã£ãŒã«ææçã®æ²»çè¬ã«ã¯ãæãŠã€ã«ã¹ãæèãæçèè¬ãããã³ç åæ§çç©ãæšçããã³æé€ããããã«èšèšãããæéº»è¬ãå«ãŸããŸãã ãããã®è£œåã¯ã埮çç©ã®ã¬ããªã±ãŒã·ã§ã³ãé»å®³ããããå ç«åå¿ã匷åãããããã¹ã现èã«ç åäœçµåã鲿¢ããããããªã©ãããŸããŸãªã¡ã«ããºã ãéããŠæ©èœããŸãã çŸä»£ã®æ²»çè¬ã¯ãã¢ãã¯ããŒãã«æäœã... ãã£ãšèŠã
Mitochondrial Disorders æ²»çåžå ŽèŠæš¡ãšäºæž¬ â 2025 â 2032ã°ããŒãã«ã»ããã³ã³ããªã¢åŠçåžå ŽèŠæš¡ã¯ã2025幎ã«1.2åç±³ãã«ã§è©äŸ¡ããã2032幎ãŸã§ã«2.6åç±³ãã«ã«éãããšäºæ³ããã2025幎ãã2032幎ãŸã§ã®11.3%ã®ååç©ã®å¹Žéæé·ç(CAGR)ã瀺ãããããã£ãŒã«Mitochondrialç¡ç§©åºã®åŠçœ®ã¯æ©èœäžå šã®ããã³ã³ããªã¢ã«ãã£ãŠåŒãèµ·ãããã现èãšãã«ã®ãŒäžè¶³ãç®æšãšããŸããã çŸåšã®æ²»ç補åã«ã¯ãã³ãšã³ã¶ã€ã Q10ãL-ã«ã«ããã³ãããã³ã³ããªã¢æ©èœã匷åããé žåã¹ãã¬ã¹ã軜æžããæé žåãµããªã¡ã³ããå«ãŸããŠããŸãã å®éšè¬ã¯ãããã³... ãã£ãšèŠã
ãã§ãã«ã±ãã³ãªãš æ²»çåžå ŽèŠæš¡ãšäºæž¬ - 2025 - 2032ã°ããŒãã«Phenylketonuria æ²»çåžå ŽèŠæš¡ã¯ã2025幎ã«1.2åç±³ãã«ã§è©äŸ¡ããã2032幎ãŸã§ã«2åç±³ãã«ã«å¢å€§ããèŠèŸŒã¿ã§ã2025幎ãã2032幎ãŸã§ã®8.5%ã®ååç©å¹Žéæé·ç(CAGR)ãå±ç€ºããŠããŸãããããã£ãŒã«Phenylketonuria (PKU)ã®åŠçœ®ãããã¯ãã¯èçœè³ªè±å¯ãªé£ç³§ã§èŠã€ããããã¢ããé žã®ãã§ãã«ã¢ã©ãã³ãæ°é³ä»£è¬ããããã£ã®äžèœã管çããããã«èšèšãããŠããŸãã ã³ã¢è£œåã«ã¯ãå®å šãªã¢ããé žã¬ãã«ãç¶æããªãããå¿ é æ é€çŽ ãæäŸããå»çé£åãšãã§ãã«ã¢ã©ãã³ããªãŒåŠæ¹ãå«ãŸããŠ... ãã£ãšèŠã
åç©æ é€åžå ŽèŠæš¡ãšäºæž¬ - 2025 - 2032ã¢ããã«æ é€åžå ŽèŠæš¡ã¯ã2025幎ã®USD 52.7åã§è©äŸ¡ããã2032幎ãŸã§ã«82.4åç±³ãã«ã«éãããšäºæ³ããã2025幎ãã2032幎ãŸã§ã®6.5%ã®ååç©ã®å¹Žéæé·ç(CAGR)ãå±ç€ºããŠããŸãããããã£ãŒã«åç©æ é€è£œåã¯ãé£Œææ·»å ç©ããµããªã¡ã³ããããã³ãã¬ããã¯ã¹ãæé©åããããã«é å çç£ç© æé·ãå ç«ãçç£æ§ã ãããã®è£œåã¯ãã¢ããé žããã¿ãã³ãããã©ã«ãé µçŽ ããããã€ãªãã£ã¯ã¹ãªã©ã®å¿ é æ é€çŽ ãäŸçµŠããå¥åº·ãªä»£è¬ãšæ¶åããµããŒãããŸãã é ªèŸ²å Žã家犜ã逿®ããã³ä»²éã®åç©ãå«ãçš®ã幎霢ããã³çç£ã®ç®çã«åºã¥ããŠããããã¯ã«... ãã£ãšèŠã
å°åååãã¬ãã£ã«ãã·ãªã³ãžåžå Žã¯ãUSD 21.01ã§è©äŸ¡ããããšæšå®ããã 2025幎ã®Bnã¯ã2032幎ã«USD 29.96 Bnã«éãããšäºæ³ããã2025幎ãã2032幎ãŸã§ã®5.2%ã®ååç©å¹Žéæé·ç(CAGR)ãå±ç€ºããŠããŸãã ã°ããŒãã«å°ååãã¬ãã£ã«ãã·ãªã³ãžåžå Žã«é¢ããã¢ããªã¹ãã®æèŠ:ãã¬ãã£ã«ãã·ãªã³ãžã¯ äœ¿ãæšãŠã·ãªã³ãž ãã§ã«æ³šå ¥ãããç©è³ªã§æºããããŠããŸãã æ¢ã«æ³šå ¥ã®æ¶²äœãå«ãã§ããæºããããã¹ãã€ãã ãã¬ãã£ã«ãã·ãªã³ãžã¯ãã¡ãŒã«ãŒã«åãä»ããããéã§è¬ã1åæäžããã åžå Žã®éžæã«ããæ°è£œåã®çºå£²ãå¢å ãããæ ¢æ§çŸæ£ã®å¢å ãèªå·±æ³šå°è£ çœ®ã®æ¡çšã¯ãåžå Žã§æ... ãã£ãšèŠã
èªéçæ²»çåžå ŽèŠæš¡ãšäºæž¬ - 2025 - 20322025幎ïœ2032幎ã«ãããŠãäžçèªéçæ²»çåžå ŽèŠæš¡ã¯ãUSD 4.5åç±³ãã«ã«çžåœããèŠèŸŒã¿ã§ã2032幎ãŸã§ã«USD 8.3åãã«ã«éããèŠèŸŒã¿ã§ã2025幎ãã2032幎ãŸã§ã®8.2%ã®ååç©å¹Žéæé·ç(CAGR)ãå±ç€ºããŠããŸãããããã£ãŒã«èªéçé害治ç補åã¯ãæ£è ã«ãããèªç¥ã瀟äŒçãé©å¿æ©èœã®æ¹åãç®çãšããè¡åãè¬çåŠçãããã³æ¯æçä»å ¥ã䌎ããŸãã è¬çåŠç補åã¯ãåºæ¿æ§ãéææ§ããŸãã¯äžå®ãªã©ã®çŠå¿çç¶ã«å¯ŸåŠããŸãããã°ãã°ãæç²Ÿç¥è¬ãåºæ¿å€ãããã³éžæçã»ãããã³æå¶å€(SSRI)ãå«ã¿ãŸãã éãã©ãã°è£œåã«ã¯ãè¡å... ãã£ãšèŠã
è现è ã«ã«ãããŒãå»è¬ååžå ŽèŠæš¡ãšäºæž¬ â 2025 â 2032ã°ããŒãã«è现è çè¬ åžå ŽèŠæš¡ã¯2025幎ã®USD 6.8åã§è©äŸ¡ããããšæšå®ããã2032幎ã«11.5åç±³ãã«ã«éããèŠèŸŒã¿ã§ã2025幎ãã2032幎ãŸã§ã®8.1%ã®ååç©å¹Žéæé·ç(CAGR)ãå±ç€ºããŠããŸãããããã£ãŒã«è现è ã«ã«ãããŒãè¬ã¯ãè «ç墿®ãé»å®³ããå ç«ç³»ã調ç¯ããããæªæ§çްèã«ãããã¢ãããŒã·ã¹ãèªçºããããšã«ãããåçºæ§èçã管çããããã«éçºãããå»è¬åãå°éãšããŠããŸãã ãããã®è£œåã¯ãå°ååãããŒãŒé»å®³å€ããã§ãã¯ãã€ã³ãé»å®³å€ãããã³ã±ã¢ãšã³ãã©ã€ãŒãŒã·ã§ã³ãªã©ã®ããŒã«ã©ã€ãºãããçæ³ãšã®... ãã£ãšèŠã
èããæ²»çåžå ŽèŠæš¡ãšäºæž¬ - 2025 - 2032ã°ããŒãã«èããæ²»çè¬ åžå ŽèŠæš¡ã¯2025幎ã§8.2åç±³ãã«ã§è©äŸ¡ããã2032幎ãŸã§ã®9.3%ã®ååç©å¹Žéæé·ç(CAGR)ãå±ç€ºããUSD 15.7åç±³ãã«ã«éãããšäºæ³ãããããããã£ãŒã«èããã®æ²»çè¬ã«ã¯ãè现èç(HCC)ãä»ã®èæªæ§è «çãæšçãšããããã«èšèšãããå»è¬åãå«ãŸããŸãã ãããã®çæ³ã¯ãæšçãããŒãŒé»å®³å€ãå ç«çæ³ãã¢ãã¯ããŒãã«æäœãååŠçæ³å€ãããã³è «çã®é²è¡ãé ãããè»¢ç§»ãæžãããæ£è ã®çåãæ¹åããããšãç®çãšããçµã¿åããçæ³ã䌎ããŸãã çµå£ããã³æ³šå°å¯èœãªè£œå€ã¯ããã€ãªã¢ãã€ã©ããªãã£ãè代è¬ãããã³æ£... ãã£ãšèŠã
ã·ããã€ã¢ã«ãµã«ã³ãæ²»çåžå ŽèŠæš¡ãšäºæž¬ â 2025 â 2032äžççãªSynovial Sarcomaã®åŠçœ®ã®åžå Žã®ãµã€ãºã¯2025幎ã®USD 715,000,000ã§è©äŸ¡ããã2032幎ãŸã§ã®æ··åç©ã®å¹Žéæé·ç(CAGR)ã2025ãã2032幎ãŸã§æºãããšæåŸ ãããŸãããããã£ãŒã«ã·ããã€ã¢ã«ãµã«ãæ²»çã¯ããã®ãŸãã§ç©æ¥µçãªè»çµç¹çã管çããããã«èšèšãããæ²»ç補åã®ç¯å²ãå å²ããŸãã ç¬¬äžæ¬¡æ²»çã¢ãããŒãã¯ããã°ãã°ãããœã«ãã·ã³ããã³ã€ãªã¹ãã¡ããã®ãããªè¬ã䜿çšããŠæŸå°ç·çæ³ããã³ååŠçæ³ã«ãã£ãŠè£å®ãããå€ç§çåé€ãå«ãã§ããŸãã æ°èŠã«ã¿ãŒã²ãããçµã£ãçæ³ãšå ç«çæ³ã¯ãSY... ãã£ãšèŠã